MedTrace Logo

Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study

NCT01679964 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2016-09-15

No results posted yet for this study

Summary

Switching from the ritonavir-boosted protease inhibitor component to raltegravir in stable HIV-infected adult patients receiving combination therapy will demonstrate improved clinical tolerability or lipid profiles with sustained plasma virological response (\<50 copies/ml).

Conditions

  • HIV Infection
  • Adverse Drug Reaction
  • Quality of Life

Interventions

DRUG

Raltegravir switch

Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)

Sponsors & Collaborators

  • Lin, Hsi-Hsun, M.D.

    lead INDIV

Principal Investigators

  • Hsi-Hsun Lin, MD · E-DA Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01679964 on ClinicalTrials.gov